On the afternoon of February 11, Joincare Pharmaceutical Group Industry Co.Ltd(600380) (600380, SH) held the first extraordinary general meeting of shareholders in 2022 in the conference room of Joincare Pharmaceutical Group Industry Co.Ltd(600380) group building in Nanshan District, Shenzhen. The meeting deliberated and adopted the proposal on changing some investment projects with raised funds, etc.
At the meeting, Joincare Pharmaceutical Group Industry Co.Ltd(600380) Board Secretary Zhao Fengguang said in response to a reporter’s question from the daily economic news that the phase III clinical trial of covid-19 vaccine v-01 of the company in Pakistan and other countries is progressing smoothly and is expected to be applied for listing this year. Zhao Fengguang said that it was impossible to predict the sales of v-01 after it was approved for listing.
